- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02690961
Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
May 2, 2017 updated by: Tianjin Chasesun Pharmaceutical Co., LTD
Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance,Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
BeiJing, Beijing, China
- Peking Union Medical College Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Gender: male or female, each sex ratio does not exceed 2/3;
- 18-45 years (including upper and lower limit), the general situation is good;
- Body mass index (BMI) in 19-28 (including upper and lower limit of the range), bodyweight(BW)≥ 50kg (female) and 60kg (male);
- Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;
- Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.
Exclusion Criteria:
- Primary disease in important organs;
- Mental or physical disability;
- Familial hereditary disease;
- Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90 millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;
- Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;
- History of immunodeficiency diseases, including HIV antibody positive;
- Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C / syphilis positive;
- Alcohol and drug abusers;
- Who is addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;
- Any discharge period may affect the study drug, or in the past 3 months participated in any drug clinical trials;
- Before entering the group 4 weeks using any prescription drugs before entering the group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics, etc.), or into the group within 2 weeks before taking effect of drug metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form(CRF);
- The last 3 months had a history of blood donation or significant blood loss (more than 400ml);
- There are drugs, the clinical significance of the history of food allergy and atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs or similar drug allergy test;
- Lactating women, pregnant women or unable to take effective contraceptive measures;
- Researchers believe that participants not suitable to take the test for other factors .
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Kukoamine B Mesilate 0.06mg/kg
Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
Experimental: Kukoamine B Mesilate 0.12mg/kg
Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
Experimental: Kukoamine B Mesilate 0.24mg/kg
Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
Experimental: Placebo 0.06mg/kg
Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
|
Experimental: Placebo 0.12mg/kg
Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
|
Experimental: Placebo 0.24mg/kg
Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events.
Time Frame: 14 days
|
adverse event, physical examination, monitoring of vital signs, Laboratory examination, electrocardiogram(ECG).
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])
Time Frame: the first day,the sixth day(before the three injections from bottom),the seventh day
|
before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.
|
the first day,the sixth day(before the three injections from bottom),the seventh day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameters(Area Under Curve [AUC])
Time Frame: the first day,the sixth day(before the three injections from bottom),the seventh day
|
before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.
|
the first day,the sixth day(before the three injections from bottom),the seventh day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Shuai Chen, Tianjin Chasesun Pharmaceutical Co., LTD
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
June 14, 2016
Study Completion (Actual)
June 14, 2016
Study Registration Dates
First Submitted
February 5, 2016
First Submitted That Met QC Criteria
February 19, 2016
First Posted (Estimate)
February 24, 2016
Study Record Updates
Last Update Posted (Actual)
May 3, 2017
Last Update Submitted That Met QC Criteria
May 2, 2017
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HR-KB103
- ChiCTR-TRC-14005111 (Registry Identifier: Chinese Clinical Trial Registry)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Kukoamine B Mesilate
-
Tianjin Chasesun Pharmaceutical Co., LTDSouthwest Hospital, ChinaCompleted
-
Swiss Group for Clinical Cancer ResearchTerminatedAdenocarcinoma | Breast CancerSwitzerland
-
Lee's Pharmaceutical LimitedUnknown
-
Eisai LimitedCompleted
-
Eisai Korea Inc.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
Yonsei UniversityTerminatedLiver DiseaseKorea, Republic of
-
Heinrich-Heine University, DuesseldorfThe Federal Ministry of Health, Germany (Bundesministerium für Gesundheit...CompletedCorona Virus Infection | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 PCR Test PositiveGermany
-
First Affiliated Hospital of Zhejiang UniversityEnrolling by invitationNon Small Cell Lung CancerChina
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly